Who are Pregabalin plus BBCET's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pregabalin-plus-bbcet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Pregabalin plus BBCET — Competitive Intelligence Brief

Pregabalin plus BBCET (Pregabalin plus BBCET) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant, Analgesic, Antidepressant, Opioid partial agonist. Area: Pain, Depression, Substance use disorder.

phase 3 Anticonvulsant, Analgesic, Antidepressant, Opioid partial agonist Voltage-gated calcium channels, Opioid receptors, Dopamine transporter, Norepinephrine transporter Pain, Depression, Substance use disorder Small molecule Live · refreshed every 30 min

Target snapshot

Pregabalin plus BBCET (Pregabalin plus BBCET) — University of Maryland, Baltimore. Pregabalin is an anticonvulsant and analgesic drug that modulates voltage-gated calcium channels, reducing excitatory neurotransmitter release. BBCET is a combination of Bupropion, an antidepressant, and buprenorphine, an opioid partial agonist.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pregabalin plus BBCET TARGET	Pregabalin plus BBCET	University of Maryland, Baltimore	phase 3	Anticonvulsant, Analgesic, Antidepressant, Opioid partial agonist	Voltage-gated calcium channels, Opioid receptors, Dopamine transporter, Norepinephrine transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant, Analgesic, Antidepressant, Opioid partial agonist class)

University of Maryland, Baltimore · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pregabalin plus BBCET — Competitive Intelligence Brief. https://druglandscape.com/ci/pregabalin-plus-bbcet. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab